The Minister of Health, Alexandre Padilha, was in Guarulhos (SP) this Monday (17) to receive the first batch of more than two million units of insulin glargine, which serves people with type 2 diabetes.
“Today is a great day for SUS [Sistema Único de Saúde]a great day for health sovereignty in Brazil and a great day for the safety of patients who have type 2 diabetes”, said the minister at a press conference at Guarulhos Airport.
Already offered to those with type 1 of the disease, the product was acquired through a Partnership for Productive Development (PDP) and technology will be transferred to the public laboratory Bio-Manguinhos (Fiocruz).
Like this, the medicine will be produced in the country, which will make Brazil no longer dependent on foreign markets.
“It’s security, because it means that this patient is not subjected to international insulin crises, as they exist today,” stated the minister.
Check the information on Brazil Afternoon Reporterfrom the TV Brasilon the subject:
For Padilha, treatment with insulin glargine is a major advance: “It is easier to use and the response is also better.”
The production of the medicine in Brazil will be carried out by Friocruz together with Biomm in a partnership with the Chinese company Gan&Lee, one of the world’s largest insulin producers.
“It is a partnership that takes place due to the strengthening of the SUS, the decision of the Ministry of Health together with states and municipalities to start offering insulin glargine also to those with type 2 diabetes”, explains Padilha.
The expectation, according to the minister, is that with the transfer of technology to Fiocruz, production – in the state of Ceará – will reach somewhere around 30 to 40 million units per year.
“It’s a great partnership that brings guarantee and security to Brazilian patients.”
Currently, around 20 million people have diabetes in the country.
According to the minister, in addition to this shipment, Brazil will receive another 4.7 million units by the end of the year, reaching almost seven million. Like this, The federal government’s investment in combating diabetes, in 2025, will be R$131.8 million.
